FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.

This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or metastatic breast cancer. PMID: 31649043 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31649043?dopt=Abstract

Source: Clinical Cancer Research - October 23, 2019 Category: Cancer & Oncology Authors: Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, Theoret MR, Amiri-Kordestani L, Pazdur R, Beaver JA Tags: Clin Cancer Res Source Type: research